No Benefit for Stent Versus Medical Therapy in Stable CAD
Mar 01, 2012 |
Kathleen Stergiopoulos, M.D., Ph.D., and David L. Brown, M.D., of the Stony Brook University Medical Center in New York, conducted a meta-analysis of eight prospective randomized clinical trials identified from the literature and involving 7,229 patients who underwent either initial coronary stent implantation or medical therapy for treatment of stable CAD. The effect of each intervention on the mortality rate and incidence of nonfatal myocardial infarction, unplanned revascularization, and persistent angina was investigated.
The researchers found that the respective event rates for death after an average 4.3-year follow-up period were 8.9 percent with stent implantation and 9.1 percent with medical therapy (odds ratio [OR], 0.98; 95 percent confidence interval [CI], 0.84 to 1.16). The incidence of nonfatal myocardial infarction was 8.9 and 8.1 percent for stent implantation and medical therapy, respectively (OR 1.12; 95 percent CI, 0.93 to 1.34). Rates of unplanned revascularization (21 and 34 percent, respectively; OR, 0.78; 95 percent CI, 0.57 to 1.06) and persistent angina (29 and 33 percent, respectively; OR, 0.80; 95 percent CI, 0.60 to 1.05) were also similar between the two intervention groups.
"Initial stent implantation for stable CAD shows no evidence of benefit compared with initial medical therapy for prevention of death, nonfatal myocardial infarction, unplanned revascularization, or angina," the authors write.
[Health care workers who are involved in procedures utilizing radiation more often report experiencing work-related musculoskeletal pain, according to a study published in the March 3 issue of the Journal of the American College of Cardiology.
Sanofi’s Toujeo (insulin glargine [rDNA origin] injection, 300 U/mL) is a once-daily, long-acting basal insulin product designed to improve glycemic control in adults with type 1 and/or type 2 diabetes.
Younger women may ignore early warning signs of an acute myocardial infarction, a new study reveals. The finding could help explain why younger women have higher rates of death from AMI than men in their age group. The study was published online Feb. 24 in Circulation: Cardiovascular Quality and Outcomes.
For aspirin-sensitive patients undergoing everolimus-eluting stent implantation, 6-month dual antiplatelet therapy is noninferior to 24-month DAPT, according to a study published in the March 3 issue of the Journal of the American College of Cardiology.